Agios Pharmaceuticals
AGIO
156 hedge funds and large institutions have $2.39B invested in Agios Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 45 reducing their positions, and 25 closing their positions.
47% more capital invested
Capital invested by funds: $1.63B → $2.39B (+$764M)
31% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 45
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
4.16% more ownership
Funds ownership: 92.87% → 97.02% (+4.2%)
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
3% less funds holding
Funds holding: 161 → 156 (-5)
20% less call options, than puts
Call options by funds: $14.3M | Put options by funds: $17.9M
Top Buyers
| 1 |
BlackRock
New York
|
+$103M |
| 2 |
Goldman Sachs
New York
|
+$27.4M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$20.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$10.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.82M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$9.82M |
| 2 |
CCI
Columbus Circle Investors
|
-$9.1M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$5.35M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.65M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.19M |
AGIO Hedge Fund Activity: Q1 2017 in Review
156 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2017, worth a combined $2.39B — up 47% from $1.63B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AGIO positions and 25 closed out — a net gain of 1 holder — while 59 added to existing stakes and 45 trimmed.
The largest buyer was BlackRock, adding an estimated $103M. The largest seller was Millennium Management, cutting an estimated $9.82M.
- 156 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2017, down from 161 in Q4 2016.
- Funds reported $2.39B of Agios Pharmaceuticals stock for Q1 2017, up 47% quarter-over-quarter.
- 26 funds opened new Agios Pharmaceuticals positions in Q1 2017 and 25 closed out, a net change of +1 holder.
- The largest Agios Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $103M added.
- The largest Agios Pharmaceuticals seller in Q1 2017 was Millennium Management, an estimated $9.82M sold.
Based on aggregated 13F filings for Q1 2017.